Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING Phase 3

SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity

NCT04775082 · View on ClinicalTrials.gov ↗

Study Summary

The study looks at how liraglutide works on participant's body weight. Researchers will look at how liraglutide can help children with obesity to lose weight. They will look at how much weight the children will lose, and if there are any side effects. Participants will either get liraglutide or placebo. Which treatment the participants get is decided by chance. Liraglutide is a new medicine for children, but it can already be prescribed by doctors to adults with overweight or obesity. The participant will get 1 injection every day. In addition to taking the medicine, the participants will have talks with the study staff about healthy food choices, how they can be more physically active and what can be done to help the participants to lose weight. The study will last for about 96 weeks (almost 2 years). The participants will have 18 clinic visits and 10 phone or video calls with the study doctor/staff. Participant will have blood samples taken, have 1 test to check the heart, 1 hand X-ray taken and must fill in a diary between some of the visits.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Liraglutide

Study Locations (20)

Other

  • UZ Brussel — Brussels
  • UZ Leuven - Kindergeneeskunde — Leuven
  • Mamc & Lnjp — New Delhi
  • Rambam MC - Department of Pediatrics A — Haifa
  • Schneider MC - Endrocrinology and Diabetes — Petah Tikva
  • Hospital Putrajaya — Putrajaya
  • Consultorio de Endocrinología y Pediatría — Puebla City
  • Hospital Da Luz S.A. — Lisbon
  • Hospital da Luz — Lisbon

Arizona

  • TMC Hlthcr Clin Res Office — Tucson

Colorado

  • Children's Hospital Colorado — Denver

Idaho

  • Solaris Clinical Research — Meridian

Louisiana

  • Pennington Biom Res Ctr — Baton Rouge

Maryland

  • Barry J. Reiner, MD LLC — Baltimore

Minnesota

  • University of Minnesota_CPOM — Minneapolis

New York

  • UBMD Peds-Div of Endo/Diabetes — Buffalo

Trial Details

FieldValue
Enrollment Target 78 participants
Start Date 2021-03-04
Est. Completion 2027-01-15
Phase Phase 3

Sponsor

Novo Nordisk A/S

189 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04775082

The ClinicalTrials.gov registry entry for NCT04775082 describes a study currently listed as active not recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 189 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04775082 reports 20 study locations spanning 12 distinct geographic areas — top geographies include Other, Arizona, Colorado. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04775082 about?

NCT04775082 is a clinical study titled "SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity". The study looks at how liraglutide works on participant's body weight. Researchers will look at how liraglutide can help children with obesity to lose weight. They will look at how much weight the children will lose, and if there are any side effects. Participants will either get liraglutide or pla...

What is the current status of trial NCT04775082?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 78 participants. The study started on 2021-03-04. Estimated completion is 2027-01-15.

What conditions does trial NCT04775082 study?

This clinical trial studies the following conditions: Obesity. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT04775082?

The interventions under investigation include: Placebo (DRUG), Liraglutide (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT04775082?

This trial is sponsored by Novo Nordisk A/S, which has 189 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04775082 being conducted?

This trial has 20 study locations across Arizona, Colorado, Idaho, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial